Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb open-label randomized study of dolutegravir/abacavir/lamivudine versus atazanavir/ritonavir plus tenofovir/emtricitabine in treatment-naive women with HIV-1
2012-005823-34Phase 3Unknown
- Sponsor
- ViiV Healthcare
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing DTG/ABC/3TC FDC once daily with ATV + RTV + TDF/FTC once daily (2 arms). Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at Week 48. Status: unknown.
02
Drugs
dolutegravirabacavirlamivudineatazanavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-005823-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005823-34.